[ad_1]
Although Germany’s BioNTech and US-based Pfizer are working hard to produce coronavirus vaccines, the founders warn there could be supply disruptions to Europe until products from other pharmaceutical companies hit the market, Reuters reported.
As the European Union authorities took longer to approve the vaccine than other countries and Brussels did not order large quantities of vaccines, the vaccines reach the European market more slowly, even if the German company was the first to win the vaccine competition.
At the moment, the situation is not so good and there will be stagnations until more vaccines are approved, in the meantime, the deficit must be filled.
He told Spiegel ORgramyou Sahin, CEO of BioNTech. He also spoke that he said the European Union could do about the situation, as the United States had already pledged 600 million doses of the vaccine, while the union waited until November to order half of that.
[ad_2]
